Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling
Hepatocellular carcinoma (HCC) is one of the most lethal tumours worldwide. However, the effects of first-line sorafenib treatment in advanced HCC fail to prolong patients’ survival due to the highly heterogeneous characteristics of HCC etiology. Cyclin-dependent kinase 9 (CDK9) is an important targ...
Saved in:
Published in | Acta pharmacologica Sinica Vol. 43; no. 4; pp. 1033 - 1045 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Singapore
Springer Singapore
01.04.2022
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!